Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: George T. Santamaria who wrote (2503)	10/27/1997 1:42:00 AM
From: Joe E.	Read Replies (1) \| Respond to of 6136

Re Agouron drop Friday: I think the cause of the drop was the Chemokine news (BTW John W. I do not know how long these chemicals have been known/researched/considered as treatment possibilities). As we have seen AGPH moves on news of potential competitors. Some others think the cause of the drop was the insider selling news. [On the subject of insider selling news - selling by the very top people probably means that a takeover is not in the immediate future, which can be a depressant for the stock price. Otherwise, it means little IMO.] No doubt the cause of the drop was somewhat related to the general market nervousness over the Asian tiger countries. (They have minimal influence on AGPH's valuation as only Singapore and Hong Kong have the wealth to pay for this drug for any significant number of people, and their populations are not large.) On other subjects: This weekend's Barrons shows that the number of AGPH shares sold short have declined since last month, which is good for the stock, IMO, since it shows that at least some shorts have changed their minds. Probably because of the good earnings news. Fearless suggestion for the week ahead: Go ahead and buy this week if you get a chance to do so at 44 or better, as you won't likely get another. At 44 I calculate AGPH to be 25% undervalued, or so. No refunds are offered if this suggestion turns out to be stupid. I think I will do a buy-write this week, as I love the option premiums offered on his stock. Later this month or next when the European approval news comes out (I hope)the stock will likely jump (probably IMO not to 70, though). Then the buy-write will look really timid and I will be almost ashamed to accept the money (I hope).